Loading organizations...
§ Private Profile · Columbus, OH, USA
Biotech company developing biologic therapies targeting bacterial biofilms for persistent respiratory infections.
Clarametyx Biosciences is a Columbus, Ohio-based biotechnology company that develops immune-enabling biologic therapies and vaccines targeting bacterial biofilms to treat severe persistent infections. The clinical-stage firm focuses on addressing chronic respiratory diseases, specifically cystic fibrosis and hospital-acquired pneumonia, by rendering infections vulnerable to immune responses and standard antibiotics. The company operates with $33 million in Series A financing to advance its clinical pipeline, which includes the recent completion of a Phase 2a study for its lead monoclonal antibody candidate, CMTX-101. Clarametyx utilizes foundational technology originally licensed from Nationwide Children’s Hospital and is currently led by Chief Executive Officer David Richards, alongside senior executives Veronica L. Hall and Brendan Doran. The organization was officially established in 2020 by a founding team consisting of Charles McOsker, Juliana Woda, Michael Triplett, and Peter G. Kleinhenz.
Clarametyx Biosciences has raised $51.1M across 3 funding rounds.
Clarametyx Biosciences has raised $51.1M in total across 3 funding rounds.
Clarametyx Biosciences has raised $51.1M in total across 3 funding rounds.
Clarametyx Biosciences's investors include Bill Baumel, 1776, C Bio Investors, Cystic Fibrosis Foundation, JobsOhio Growth Capital, Nationwide Children, Rev1 Ventures.
Clarametyx Biosciences has raised $51.1M across 3 funding rounds. Most recently, it raised $33.0M Series A in January 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 5, 2024 | $33M Series A | Bill Baumel | 1776, C BIO Investors, Cystic Fibrosis Foundation, JobsOhio Growth Capital, Nationwide Children, Rev1 Ventures | Announced |
| Apr 4, 2022 | $3.9M Grant | — | — | Announced |
| Nov 18, 2020 | $14.2M Venture Round | — | — | Announced |